Instem and Histofy Launch AI-Powered Software to Accelerate Preclinical Study Reporting

0
13
Vik Krishnan

BOSTON–Instem and Histofy have formed a strategic partnership to introduce Provantis Compose, an artificial intelligence-assisted software tool designed to automate report preparation and reduce the time required to complete nonclinical research documentation.

The new module integrates Histofy’s AI-assisted reporting technology with Instem’s Provantis platform, which supports life sciences research and regulatory operations.

According to Instem, the software can reduce the time required to prepare a draft nonclinical study report from approximately two weeks to four hours, while maintaining scientific oversight and review requirements.

Provantis Compose is designed to automate the collection, organization, and drafting of information generated during preclinical research.

The system uses data stored in Instem’s Provantis, Pristima, and Climb platforms to assemble comprehensive draft reports containing study results, statistical analyses, pathology findings, supporting documentation, and other relevant information.

The companies said the technology is intended to reduce the administrative workload associated with preparing final study reports, allowing researchers to spend more time on scientific analysis and decision-making.

“Provantis Compose represents the next evolution of the digital study lifecycle,” said Vik Krishnan, Chief Executive Officer of Instem.

“Our customers have consistently told us that final report preparation remains one of the most time-consuming and resource-intensive stages of study execution. By partnering with Histofy, we have created a solution that enables study teams to move from completed data collection to a completed draft report in four hours rather than two weeks while still ensuring that qualified scientists remain responsible for reviewing, approving, and standing behind every conclusion.”

The platform is designed for researchers involved in nonclinical drug development, including study directors, toxicologists, pathologists, and scientific report authors.

Nonclinical studies are an important part of pharmaceutical and biotechnology research, generating data used to assess the safety and biological effects of experimental treatments before they advance into human clinical trials.

Preparing final reports from these studies can require extensive data compilation, analysis, and documentation to support regulatory submissions.

Provantis Compose seeks to streamline that process by automatically organizing research data into structured drafts that scientists can review and finalize.

The companies emphasized that the software does not replace scientific judgment or regulatory accountability.

All AI-generated report content must be reviewed, edited, and approved by qualified scientific personnel before a report is finalized.

The approach incorporates a human-in-the-loop review process intended to preserve scientific accuracy and accountability while reducing repetitive administrative tasks.

“Instem has the platforms where the nonclinical study data already lives; Histofy has the cutting-edge technology to turn the study data into a high-quality report draft. Together, we can give scientists their time back without asking them to give up control of the science – and report drafting is only the first part of the study lifecycle we intend to take on together,” said Nasir Rajpoot, Chief Executive Officer and Chief Scientific Officer of Histofy.

The launch follows Instem’s announcement of a unified, AI-enabled Provantis platform designed to integrate multiple stages of preclinical research and development.

The broader platform includes three components: Provantis LAB, Provantis INSIGHTS, and Provantis SUBMIT.

Together, the systems are intended to support laboratory operations, research data analysis, and regulatory submission activities.

Provantis Compose is immediately available to Provantis LAB customers, while additional capabilities are being developed as part of the broader platform’s planned mid-2027 release.

Instem said the partnership with Histofy could eventually extend AI-assisted automation into other stages of the nonclinical research process.

The companies expect the technology to improve productivity by reducing manual report preparation and accelerating the transition from completed research studies to finalized scientific documentation.

Leave A Reply

Please enter your comment!
Please enter your name here